List of Prezcobix drug patents

Prezcobix is owned by Janssen Prods.

Prezcobix contains Cobicistat; Darunavir.

Prezcobix has a total of 6 drug patents out of which 0 drug patents have expired.

Prezcobix was authorised for market use on 29 January, 2015.

Prezcobix is available in tablet;oral dosage forms.

Prezcobix can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.

The generics of Prezcobix are possible to be released after 06 October, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(1 year, 19 days from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

US8148374 JANSSEN PRODS Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(1 year, 6 months from now)

US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(4 years from now)

US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; Treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of PREZCOBIX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic